Nordion's constantly evolving business will soon be without proprietary pharma, as the company has agreed to ship out its targeted therapies business for $200 million.
Navidea Biopharmaceuticals has seen its fair share of CMO troubles, as problems with its last contract manufacturer delayed a much-anticipated FDA approval. Now, the diagnostics developer is hitching up with Nordion to manufacture an in-development imaging agent, hoping to avoid more production setbacks.
The agenda for the mammalian synthetic biology workshop held at the Massachusetts Institute of Technology last weekend demonstrates that renewed interest in vaccines has opened up new therapeutic targets, which in turn has driven new approaches to manufacturing. And the threats of pandemic flu and bioterrorism have acted as an extra innovation driver.
PRA has cut the ribbon on a new facility in Wales, planning to add about 100 new jobs in its informatics unit with help from the local government.
AMRI's days of posting quarterly net losses appear to be far behind, as the company rode an 11% revenue jump to $6.5 million in net income, up from a negative $3.8 million in the same period last year.
When Sanofi bought an 80% stake in Indian vaccinemaker Shantha Biotech in 2009, the talk was of the deal accelerating growth in emerging markets.Things played out a little differently though.
AMRI has locked down another 5-year partnership with Japan's Ono Pharmaceutical, agreeing to provide development and manufacturing services for the company's treatments, which include a promising multiple sclerosis drug.
Citing a boom in demand for biologics, Catalent has cut the ribbon on a new biomanufacturing facility in Madison, WI, a plant the company says will quadruple its capacity.
The spread of H7N9 in China is a reminder of why the Department of Health and Human Services (HHS) gave Novartis $487 million to build its cell culture vaccine production plant. If H7N9 reaches the U.S., the country will be better prepared because of the investment.
Two big-time drugmakers are having to put their plans on hold thanks to problems with contract manufacturers, with GlaxoSmithKline facing a prolonged drug shortage and Allergan enduring an FDA rejection.